WHO: Research Ambassadors are members of the public who live with, or advocate for others living with a condition that falls under CIHR – IMHA’s research mandate (conditions related to bones, joints, muscles, connective tissue, skin and teeth). Research Ambassadors bridge the gap between researchers and patients, addressing the different stages of the research process known as: Basic Biomedical Science, Clinical Science and Knowledge, and Clinical Practice and Health Decision Making.
New Canadian Institutes of Health Research funding, awards, and promotions at Arthritis Research Canada will advance arthritis research, treatment and care
ACE’s scientific advisor, Arthritis Research Canada (ARC), has been awarded two Canadian Institutes of Health Research Knowledge to Action grants. Here are the names of the award recipients and a brief explanation of their research projects:
Dr. Deborah Marshall’s research, entitled “Building Partnerships to Improve Care of Early Knee Osteoarthritis Patients: Co-developing a Risk Management Tool” aims to develop a tool to help family physicians to motivate people with early osteoarthritis of the knee to institute life-style changes at a time when they can make a difference to the progress of the disease.
Dr. Paul Fortin’s research, entitled “Dissemination of the Lupus Interactive Navigator (LIN) – Measuring its Uptake and Impact on Global Health and Self-Care” will be devoted to developing an online tool to facilitate and support engagement, coping and self-management in people with lupus.
The following researchers at ARC have each been awarded a prestigious award from the science community: Continue reading →
In this issue of JointHealth™ insight, Arthritis Consumer Experts (ACE) maps out the latest news for you about provincial drug formulary listing decisions. It contains information about important changes to provincial drug formularies and what it means for Canadians living with inflammatory arthritis. The changes covered in this update affect people living with rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and juvenile idiopathic arthritis (JIA).
The following medication has been listed for reimbursement on the provincial drug formulary: Continue reading →
Researchers, patients and government come together
The conversation on new reform from the Canadian Institutes of Health Research that impacts federal research funding continues.
We commend Minister Philpott for her request for the Canadian Institutes of Health Research (CIHR) to convene a working meeting with key representatives of the research community to find common ground and move forward with solutions that address the issues around the quality and integrity of CIHR’s peer review system.
Minister Philpott’s actions are in response to views expressed within the health research community, and from patient organizations like Arthritis Consumer Experts (ACE).
All stakeholders in healthcare – governments, researchers, clinicians and patients – have an obligation to consider the impact of changes to the CIHR and Canada’s world-class standing in the scientific community and the benefits of health research for all Canadians.
Below is the message from Minister Philpott to Canada’s health research community: Continue reading →
Typing, texting, and gaming on digital gadgets are wearing out your joints. The ‘pain after texting’ phenomenon happens in both adults and children and leads to joint and wrist pains. According to hand surgeon Dr. Mark Ciaglia of Woodlands Center for Specialty Surgery in Texas, you can develop arthritis if you are excessively texting, emailing, and playing games on your digital devices. In an interview with UK’s Daily Mail, Ciaglia said: “With the advent of texting and video games and excessive use of computers and typing you’re wearing the joints out sooner so we’re actually seeing a shift in the demographics of patients that get the arthritis because they’re wearing their joints out so much sooner.” Continue reading →
State of Arthritis Medications: Some old, some new, all important
The reliable, quick reference arthritis medications guide you need to assist you and your health care team with your therapy conversations.
The JointHealth™ Medications Guide gives you information on the most commonly prescribed medications for inflammatory types of arthritis and osteoarthritis. Medication information for the following diseases is included in this year’s guide: rheumatoid arthritis, ankylosing spondylitis, juvenile arthritis, psoriatic arthritis, systemic lupus erythematosus, vasculitis, osteoarthritis, and osteoporosis.